Theravance Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
Net loss: US$56.4m (loss widened by 2.2% from FY 2023). US$1.16 loss per share (further deteriorated from US$1.00 loss in FY 2023). NasdaqGM:TBPH Earnings and Revenue Growth February 28th 2025 All figures shown in the chart above are for the trailing 12 month (TTM) period Theravance Biopharma Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 9.8%. Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 4.0% from a week ago. Balance Sheet Analysis Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Theravance Biopharma's balance sheet and an in-depth analysis of the company's
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TBPH&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma (NASDAQ:TBPH) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TBPH&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.MarketBeat
TBPH
Earnings
- 11/10/25 - Beat
TBPH
Sec Filings
- 12/8/25 - Form 8-K
- 12/5/25 - Form 4
- 12/3/25 - Form 144
- TBPH's page on the SEC website